Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : 4Q Core Operating Profit Tumbled, Expects Growth in 2020

share with twitter share with LinkedIn share with facebook
share via e-mail
02/14/2020 | 02:49am EST

By Carlo Martuscelli

 

AstraZeneca PLC (AZN.LN) said Friday that core operating profit fell in the final quarter of the year, missing analysts' expectations, and guided for growth in the year ahead.

The FTSE 100-listed drug maker reported that core operating profit slid 29% to $1.55 billion. Profit missed analysts' expectations of $1.80 billion for the closely-watched company metric that strips out one-off items.

Total revenue rose 3.9% to $6.66 billion, also falling short of analysts' expectations of $6.73 billion at the top line.

The pharmaceutical company guided for total revenue increasing a high single-digit to a low double-digit percentage in 2020, while core earnings per share are expected to rise by a mid- to high-teens percentage, all at constant exchange rates.

AstraZeneca cautioned that its guidance depends on the final impact of Covid-19, the novel coronavirus first identified in the Chinese city of Wuhan.

The current outlook is assuming that the epidemic lasts a few months, but the company said it is closely monitoring the epidemic, and will provide an update during first-quarter results.

China is a major driver of earnings for the business, with quarterly revenue climbing 25% in the period to $1.19 billion.

The company declared a dividend of $1.90 a share, bringing the total dividend at $2.80, unchanged from the year before.

 

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

 

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.53% 7690 Delayed Quote.1.09%
FTSE 100 INDEX 0.28% 7234.11 End-of-day quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
02/20EXCLUSIVE : Canadian regulator considers changes to new drug pricing plan
RE
02/18Consumer groups, unions oppose fix for planned merger of AbbVie and Allergan
RE
02/17ASTRAZENECA PLC : - Full-year and Q4 2019 results
AQ
02/14Health Care Flat Amid Mixed Earnings Season -- Health Care Roundup
DJ
02/14EUROPE : European shares settle below record highs
RE
02/14FTSE 100 ends week lower after week AstraZeneca, RBS results
RE
02/14NEWS HIGHLIGHTS : Top Company News of the Day
DJ
02/14GLOBAL MARKETS LIVE: Facebook ready to pay more taxes, Amazon gets JEDI suspe..
02/14AstraZeneca's CEO reaffirms 2021 targets
RE
02/14AstraZeneca braces for coronavirus hit, but no impact so far
RE
More news
Financials (USD)
Sales 2020 26 842 M
EBIT 2020 7 449 M
Net income 2020 3 013 M
Debt 2020 13 388 M
Yield 2020 2,84%
P/E ratio 2020 40,4x
P/E ratio 2021 27,4x
EV / Sales2020 5,37x
EV / Sales2021 4,79x
Capitalization 131 B
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 107,31  $
Last Close Price 99,69  $
Spread / Highest target 38,9%
Spread / Average Target 7,64%
Spread / Lowest Target -25,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Marcus Wallenberg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC1.09%130 836
JOHNSON & JOHNSON1.71%395 024
ROCHE HOLDING AG10.08%300 195
NOVARTIS2.89%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.50%197 679